Resistell AG closes CHF 3.5M series A financing round

D.Day 2019 – Discover what your neighbours are working on!

“This process is one of the most rapid methods in this review and can be used to develop quantitative anti-biograms”, Puttaswamy et al., 2018, Archives of Clinical Microbiology, 9:3, 83 https://doi.org/10.4172/1989-8436.100083

Well done to all our colleagues from CHUV Hospital, recently listed in the top 10 best hospitals in the world. Resistell is proud to develop the rapid AST with the support of CHUV Hospital. Thank you and congratulations!

Resistell was selected as one of ten new startups have been selected for Venture Leaders Life Sciences 2019. Chosen from among the most-promising life sciences startups in Switzerland, the team will embark on a packed, week-long roadshow in Boston. The startups will also pitch at the Startup Champions Seed Night event in Lausanne on 11 April.

"Enough time has been wasted issuing warnings about antibiotic resistance. The moment has come to do something about it" ~The Economist

Bilan selected Resistell as one of the Top 50 Swiss startups in which to invest in 2019! We are proud to be on the prestigious list with our rapid AST technology!

We thank everyone who visited our scientific presentation in Berlin at Novel Antimicrobials & AMR Diagnostics Conference (14-15.03.2019). We are looking forward to all new future partnerships and collaborations!